Lilly to buy cancer drug developer AurKa Pharma for up to $575 millionStaff Writer |
Acquisition AurKa Pharma will receive $110 million upfront
Eli Lilly and Company will buy AurKa Pharma in a deal potentially worth up to $575 million.
AurKa’s chief drug under development was discovered by Lilly, but the drugmaker sold the compound in 2016 to TVM Capital Life Science, which established AurKa.
The drug, AK-01, is being studied in early-stage trials to treat multiple types of solid tumors. ■
What to read next